Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Shares saw unusually high trading activity — 1,311,257 shares traded (a 186% increase from the prior session) as the stock moved to $5.515 from $5.01.
• Analysts show heavy coverage and a bullish consensus: the average rating is Buy with a consensus price target of $16.56, and individual targets range from $12 to $24 (3 Strong Buy, 6 Buy, 1 Sell).
• Large institutional investors increased positions in Q4 — including Paradigm Biocapital, ADAR1, UBS and Millennium — and institutions now own 19.06% of the company.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares saw strong trading volume on Tuesday . 1,311,257 shares changed hands during trading, an increase of 186% from the previous session's volume of 457,841 shares.The stock last traded at $5.5150 and had previously closed at $5.01.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IVA. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inventiva in a research note on Thursday, January 22nd. UBS Group assumed coverage on Inventiva in a report on Wednesday, January 7th. They set a "buy" rating and a $12.00 price target for the company. Leerink Partners started coverage on Inventiva in a research report on Monday, January 12th. They set an "outperform" rating and a $12.00 price target on the stock. Barclays began coverage on Inventiva in a research note on Tuesday, January 27th. They issued an "overweight" rating and a $18.00 price objective on the stock. Finally, HC Wainwright set a $24.00 target price on Inventiva and gave the company a "buy" rating in a research report on Wednesday, January 28th. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $16.56.

Inventiva Price Performance

The stock has a 50-day moving average of $6.03 and a 200 day moving average of $5.36.

Inventiva (NASDAQ:IVA - Get Free Report) last released its earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.01 million for the quarter. On average, analysts expect that Inventiva S.A. Sponsored ADR will post -2.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Inventiva

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Paradigm Biocapital Advisors LP acquired a new position in shares of Inventiva during the fourth quarter worth $18,600,000. ADAR1 Capital Management LLC acquired a new position in Inventiva in the 4th quarter worth about $12,601,000. UBS Group AG boosted its stake in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company's stock valued at $12,293,000 after purchasing an additional 2,634,580 shares in the last quarter. SymBiosis Capital Partners LLC acquired a new stake in shares of Inventiva during the fourth quarter valued at about $12,090,000. Finally, Millennium Management LLC raised its holdings in Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company's stock valued at $12,334,000 after buying an additional 2,540,540 shares during the last quarter. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.